Want to join the conversation?
$MRK and $PFE announced treatment of first patient in Phase 3 study of avelumab, investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in an advanced renal cell carcinoma (RCC) setting. The study, JAVELIN Renal 101, is first pivotal trial investigating avelumab in combination with INLYTA (axitinib), tyrosine kinase inhibitor (TKI).
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.